Analysts’ revenue estimates
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion. The company expects strong its product portfolio, recent launches, strategic initiatives, partnerships, and collaborations to drive its revenues in the quarter.
On August 22, 2017, Medtronic will announce its fiscal 1Q18 earnings for the year ended July 28, 2017. As per Wall Street estimates, the company will record 1Q18 revenue of ~$7.5 billion, representing YoY (year-over-year) growth of ~4%. The company’s fiscal 4Q17 revenue was ~$7.9 billion, a rise of ~5% YoY.
The chart above shows a comparison of Medtronic’s actual reported revenues and analysts’ estimates in recent quarters. In fiscal 4Q17, Medtronic’s actual revenue exceeded analysts’ expectations, as the company’s sales were driven by strong performances across its business segments.
Cardiac and Vascular Group (or CVG), Minimally Invasive Therapies Group (or MITG), Restorative Therapies Group (or RTG), and the Diabetes Group are the company’s four business segments. For a brief overview, read A Key Breakdown of Medtronic’s Business Model.
Johnson & Johnson (JNJ), Stryker (SYK), and Becton Dickinson (BDX) are among Medtronic’s major competitors. These companies registered revenues of ~$18.8 billion, $3 billion, and $3.1 billion, respectively, in their most recent quarters.
You can consider investing in the Vanguard Total Stock Market ETF (VTI) for diversified exposure to Medtronic. Medtronic accounts for ~0.57% of VTI’s total holdings.
Next, let’s look at the company’s earnings expectations in fiscal 1Q18.